Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Apr 11, 2007 by Edgar Snyder

Bladder Drug Needs Stronger Warning for Children

Oxybutynin

According to the Food and Drug Administration (FDA), a bladder drug used to treat overactive bladder conditions needs more specific warnings for children. Oxybutynin, sold under the brand name Diptropan, has the potential to cause hallucinations and agitation in children.

After reviewing 202 reports of central-nervous-system events, the FDA saw a higher incidence rate in children than adults. In 2006, out of 4.8 million prescriptions written for oxybutynin, 241,000 were for children age 16 and younger. The FDA mentioned 18,000 prescriptions were written for children age 5 or younger even though the drug is only approved for use in children age 5 and older.

Currently the drug’s label mentions the potential to cause central-nervous-system side effects, which include hallucinations, nervousness, and confusion. The proposed label would provide age-specific information and also warn doctors to carefully monitor patients for the side effects.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation may involve co-counsel.

Source: “FDA Says Bladder Drug Needs Children Warnings.” By Jennifer Corbett Dooren. The Wall Street Journal. April 10, 2007.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Sep 16, 2016
New CDC Tool Will Help Keep Traveling Workers Safe
Tweet